Literature DB >> 25424925

Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine.

Xue Han1, Xiao-ling Ying, Shi-li Zhou, Tao Han, Hao Huang, Qi Jin, Fan Yang, Qi-ying Sun, Xian-xun Sun.   

Abstract

Human enterovirus 71 (EV71) plays an important role in hand, foot, and mouth disease (HFMD), which recently caused the death of hundreds of children in the Asia-Pacific region. However, there are no specific treatments available for EV71 infections; thus, a safe and effective vaccine is needed urgently. In this study, we developed an effective and economical method for producing EV71 polyprotein (P1 protein) in Pichia pastoris. Furthermore, we evaluated the potential of P1 protein as a candidate vaccine against EV71 virus. The data revealed that P1 protein induced persistent high cross-neutralization antibodies for different EV71 subtypes, and elicited significant splenocyte proliferation. The high levels of interleukin-10(IL-10) and interferon-gamma (IFN-γ) showed that P1 protein induced Th1 and Th2 immune responses. Interestingly, vaccinating female mice with the P1 protein conferred cross-protection against different EV71 subtypes to their neonatal offspring.Compared with heat-inactivated EV71, the P1 protein elicited improved humoral and cellular immune responses and showed good cross-protection with different EV71 subtypes. Therefore, the EV71-P1 protein produced by P. pastoris is a promising candidate vaccine against EV71.

Entities:  

Keywords:  P1 polyprotein; Pichia pastoris; enterovirus 71; immunogenicity vaccine

Mesh:

Substances:

Year:  2014        PMID: 25424925      PMCID: PMC4896795          DOI: 10.4161/hv.29123

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  49 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial.

Authors:  Yan-Ping Li; Zheng-Lun Liang; Qiang Gao; Li-Rong Huang; Qun-Ying Mao; Shu-Qun Wen; Yan Liu; Wei-Dong Yin; Rong-Cheng Li; Jun-Zhi Wang
Journal:  Vaccine       Date:  2012-03-15       Impact factor: 3.641

Review 3.  The impact of glycosylation on the biological function and structure of human immunoglobulins.

Authors:  James N Arnold; Mark R Wormald; Robert B Sim; Pauline M Rudd; Raymond A Dwek
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

4.  Enterovirus infections and enterovirus specific T-cell responses in infancy.

Authors:  S Juhela; H Hyöty; M Lönnrot; M Roivainen; O Simell; J Ilonen
Journal:  J Med Virol       Date:  1998-03       Impact factor: 2.327

5.  Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial.

Authors:  Fan-Yue Meng; Jing-Xin Li; Xiu-Ling Li; Kai Chu; Yun-Tao Zhang; Hong Ji; Liang Li; Zheng-Lun Liang; Feng-Cai Zhu
Journal:  Hum Vaccin Immunother       Date:  2012-05-01       Impact factor: 3.452

6.  The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains.

Authors:  Yan Wu; Andrea Yeo; M C Phoon; E L Tan; C L Poh; S H Quak; Vincent T K Chow
Journal:  Int J Infect Dis       Date:  2010-10-16       Impact factor: 3.623

7.  Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection.

Authors:  Hsiao-Ling Chen; Jiun-Yan Huang; Te-Wei Chu; Tung-Chou Tsai; Che-Ming Hung; Chih-Cheng Lin; Fang-Chueh Liu; Li-Chung Wang; Yi-Ju Chen; Ming-Fong Lin; Chuan-Mu Chen
Journal:  Vaccine       Date:  2008-04-10       Impact factor: 3.641

8.  Identification of immunodominant VP1 linear epitope of enterovirus 71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in Western blots.

Authors:  D G W Foo; R X Ang; S Alonso; V T K Chow; S H Quak; C L Poh
Journal:  Clin Microbiol Infect       Date:  2007-12-08       Impact factor: 8.067

9.  Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice.

Authors:  Te-Chia Wu; Ya-Fang Wang; Yi-Ping Lee; Jen-Ren Wang; Ching-Chuan Liu; Shih-Min Wang; Huan-Yao Lei; Ih-Jen Su; Chun-Keung Yu
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

Review 10.  Strategies to develop antivirals against enterovirus 71.

Authors:  Rei-Lin Kuo; Shin-Ru Shih
Journal:  Virol J       Date:  2013-01-22       Impact factor: 4.099

View more
  1 in total

Review 1.  Enterovirus A71 Vaccines.

Authors:  Mei-Ling Li; Shin-Ru Shih; Blanton S Tolbert; Gary Brewer
Journal:  Vaccines (Basel)       Date:  2021-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.